Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 341,960	$ 406,704
Accounts receivable, net	33,762	23,296
Marketable securities	29,330	27,483
Inventories	23,047	7,584
Prepaid expenses and other current assets	31,868	22,498
Amount due from related party	943	580
Total current assets	460,910	488,145
Property and equipment, net	2,708	2,944
Operating lease right-of-use asset	7,026	7,961
Other assets	13,330	20,961
Total assets	483,974	520,011
Current liabilities:
Accounts payable	8,215	12,250
Accrued expenses and other current liabilities	84,081	68,594
Deferred revenue	117,231	100,564
Amounts due to Pfizer	38,939	32,563
Cost share advance from Pfizer	0	33,818
Operating lease liability	2,374	2,148
Amounts due to related parties	851	393
Total current liabilities	251,691	250,330
Deferred revenue, non-current	379,321	375,706
Long-term operating lease liability	5,788	7,041
Long-term debt, less current maturities (related party)	358,700	358,700
Other liabilities	1,723	1,711
Total liabilities	997,223	993,488
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 96,557,652 and 94,858,446 issued and outstanding at September 30, 2022 and March 31, 2022, respectively	2	2
Additional paid-in capital	823,021	795,935
Accumulated other comprehensive loss	(17,285)	(17,285)
Accumulated deficit	(1,318,987)	(1,252,129)
Total shareholders’ deficit	(513,249)	(473,477)
Total liabilities and shareholders’ deficit	$ 483,974	$ 520,011